AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Functional genomics and proteomics: application in neurosciences.(Neuroscience for Neurologists)

Journal of Neurology, Neurosurgery and Psychiatry

| April 01, 2004 | Wilson, K.E.; Ryan, M.M.; Prime, J.E.; Pashby, D.P.; Orange, P.R.; O'Beirne, G.; Whateley, J.G.; Bahn, S.; Morris, C.M. | COPYRIGHT 2004 British Medical Association. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

J Neurol Neurosurg Psychiatry 2004;75:529-538. doi: 10.1136/jnnp.2003.026260

The sequencing of the complete genome for many organisms, including man, has opened the door to the systematic understanding of how complex structures such as the brain integrate and function, not only in health but also in disease. This blueprint, however, means that the piecemeal analysis regimes of the past are being rapidly superseded by new methods that analyse not just tens of genes or proteins at any one time, but thousands, if not the entire repertoire of a cell population or tissue under investigation. Using the most appropriate method of analysis to maximise the available data therefore becomes vital if a complete picture is to be obtained of how a system or individual cell is affected by a treatment or disease. This review examines what methods are currently available for the large scale analysis of gene and protein expression, and what are their limitations.

**********

 
    "The Blind Man and the Elephant" 
    And so these men of Indostan 
    Disputed loud and long, 
    Each in his own opinion ~ Exceeding stiff and strong, 
    Though each was partly in the right ~ And all were in the wrong! 
    John Godfrey Saxe 

Many of the currently used methods for the analysis of function in a cell or tissue rely on measuring one single analyte at a time, with the analysis being based on a prior hypothesis of mechanisms of action or biology. By measuring only one analyte, only a limited picture is gained of the complexities of an often very dynamic situation. Rather like the tale of the six blind men and the elephant, by observing only one facet at a time, a distorted view of the situation can be achieved, and the real answer to the problem remains hidden. With the advent of whole genome maps for several key organisms including man, and the use of methods for profiling all the changes that occur in cells or tissues, it is now possible to stand back and take an unbiased view of biological processes. This is particularly the case for neuropsychiatric disease, where the complexities of the brain, its multitude of connections, and the dynamic interplay between neurones and glia make an unbiased view of disease processes particularly important. (1) Two emerging fields are now coming into general use where the global approach to gaining insight into brain function can be applied. Functional genomics is the generic term used to describe methods that analyse the various genes expressed by a cell or tissue, while proteomics aims to define the protein complement. These technologies now allow an almost complete examination of gene and protein expression using single techniques. Our aim in this article is to provide an overview of the specialised methodologies and to point out the potential pitfalls and limitations of these techniques, with particular reference to investigations on human postmortem brain samples.

FUNCTIONAL GENOMICS

Cellular function is mediated through gene expression involving the production of messenger RNA. Several methods can be employed to profile gene expression in neurological and psychiatric disorders, including differential display and microarrays, ideally coupled with real time quantitative polymerase chain reaction (Q-PCR) cross validation. These technologies can be used independently or in parallel, where they investigate mRNA transcripts quantitatively by amplification of RNA from disease and control samples, and then detection of specific complementary DNA (cDNA) or antisense RNA (aRNA) species. It is hoped that pathologically relevant pathways and disease mechanisms involved in neurological and psychiatric disorders can be revealed with these techniques.

Related articles from newspapers, magazines, journals, and more
Rosetta Biosoftware Licenses the Rosetta Resolver Gene Expression Analysis...
Press release article from: Business Wire November 21, 2005 700+ words
...announced today that the Functional Genomics Center of Zurich, Switzerland...consistency and quality for their gene expression research," said Yelena...for raw and analytical gene expression data management. The cross...wide, high-resolution gene expression analysis. ...
Sequitur Announces Functional Genomics Agreement With Genentech.
Press release article from: PR Newswire November 21, 2002 700+ words
...proprietary functional genomics technology...inhibiting gene expression. Sequitur's Functional Genomics Program offers...potential our functional genomics technology...and detect gene expression. Sequitur...
Sequitur Announces Renewal and Expansion of Multi-Year Functional Genomics...
Press release article from: PR Newswire May 22, 2003 700+ words
...Pharmaceuticals with access to its functional genomics technology has been...Sequitur's proprietary functional genomics technology accelerates...specifically inhibiting gene expression. Sequitur's Functional Genomics Program offers second...
Sequitur Expands and Renews its Functional Genomics Agreements With Pharmacia...
Press release article from: PR Newswire December 4, 2000 700+ words
...expanded the company's functional genomics license agreements with...Sequitur's proprietary functional genomics technology accelerates...specifically inhibiting gene expression. Sequitur's Functional Genomics Program offers highly...
Sequitur Announces Multi-Year Functional Genomics Agreement with Procter and...
Press release article from: PR Newswire October 9, 2001 700+ words
...with access to its functional genomics technology. Sequitur...Sequitur's proprietary functional genomics technology accelerates...specifically inhibiting gene expression. Sequitur's Functional Genomics Program offers highly...
Sequitur Licenses Functional Genomics Technology to Searle.
Press release article from: PR Newswire October 6, 1999 700+ words
...antisense functional genomics technology...inhibiting gene expression. Sequitur's Antisense Functional Genomics Program offers...Antisense Functional Genomics Technology...relating to gene expression and gene detection...
Sequitur Licenses Functional Genomics Technology to Pharmacia & Upjohn.
Press release article from: PR Newswire September 29, 1999 700+ words
...antisense functional genomics technology...inhibiting gene expression. Sequitur's Antisense Functional Genomics Program offers...Antisense Functional Genomics Technology...relating to gene expression and gene detection...
Sequitur Licenses Functional Genomics Technology to Vertex Pharmaceuticals.
Press release article from: PR Newswire September 25, 2000 700+ words
...antisense functional genomics technology...inhibiting gene expression. Sequitur's Antisense Functional Genomics Program offers...Antisense Functional Genomics Technology...relating to gene expression and gene detection...
For more facts and information, see all results
©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA